Related Experiment Videos
Antioxidant system activation in prostate cancer
M I Yilmaz1, K Saglam, A Sonmez
1Department of Internal Medicine, Gulhane Military Medical Academy, Etlik-Ankara, Turkey.
Biological Trace Element Research
|March 31, 2004
Summary
Prostate cancer patients show higher malondialdehyde (MDA) levels and lower antioxidant activity and zinc (Zn) levels compared to healthy individuals. These biomarkers aid in diagnosing benign prostatic obstruction (BPO) and prostate cancer.
Area of Science:
- Biochemistry
- Oncology
- Urology
Background:
- Prostate cancer and benign prostatic obstruction (BPO) are common in aging men.
- Biomarkers of oxidative stress and antioxidant status may differentiate these conditions.
Purpose of the Study:
- To investigate glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) activities, copper, zinc (Zn), and malondialdehyde (MDA) levels in prostate cancer patients.
- To compare these markers between prostate cancer, BPO, and healthy controls.
Main Methods:
- Enzyme activities (GSH-Px, SOD) and levels of copper, Zn, and MDA were measured.
- Prostate cancer patients were staged (organ-confined vs. advanced) and graded (Gleason score).
- Comparisons were made between prostate cancer patients, BPO patients, and healthy controls.
Main Results:
- Prostate cancer groups exhibited higher MDA levels compared to healthy and BPO groups.
- Lower antioxidant activity (GSH-Px, SOD) and Zn levels were observed in prostate cancer patients.
- MDA levels correlated with prostate cancer diagnosis and stage.
Conclusions:
- Elevated MDA and reduced Zn levels are indicative of prostate cancer.
- Plasma and erythrocyte Zn levels can assist in the differential diagnosis of BPO and prostate cancer.
- MDA levels are valuable for prostate cancer diagnosis and monitoring.